• Barclays initiated coverage on Ligand Pharmaceuticals (LGND) with an 'Overweight' rating and a $345 price target on September 25, 2026.
  • This positive outlook was partly driven by Ligand's recent financing agreement of up to $47 million with AvenCell Therapeutics, for its CAR-T pipeline and royalty rights, which was announced on September 24, 2026.
  • The stock is trading 4.08% higher at $313.82, despite broader markets generally falling on September 28, 2026.